Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 2

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 2
---
 with
certain institutional investors (the “February 2025 Purchasers”) pursuant to which the Company sold, in a registered direct
offering an aggregate of 300,700 shares (the “February 2025 Shares”) of common stock at a purchase price of $3.575 per share
in a registered direct offering priced at-the-market under the rules of Nasdaq (the “February 2025 Offering”).

The
February 2025 Shares were offered pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-280796),
which was declared effective by the Securities and Exchange Commission (the “SEC”) on July 18, 2024 as supplemented by a
prospectus supplement dated February 5, 2025, filed with the SEC on February 6, 2025 and accompanying base prospectus, pursuant to Rule
424(b)(5) promulgated under the Securities Act.

In
a concurrent private placement, the Company also issued to the February 2025 Purchasers unregistered warrants (the “February 2025
Warrants”) to purchase up to an aggregate of 300,700 shares of common stock at an exercise price of $2.95 per share. The February
2025 Warrants are exercisable upon issuance and expire twenty-four months from the date of issuance.

Pursuant
to the February 2025 Securities Purchase Agreement, the Company is required to file a registration statement with the SEC within 45 days
after the date of the February 2025 Securities Purchase Agreement to register the shares underlying the February 2025 Warrants under
the Securities Act. The Company shall use commercially reasonable efforts to cause such registration statement to become effective within
75 days following the closing date of the February 2025 Offering and to keep such registration statement effective at all times until
no February 2025 Purchaser owns any February 2025 Warrants or shares underlying the February 2025 Warrants issuable upon exercise thereof.

Any
holder will not have the right to exercise any portion of the February 2025 Warrants if the holder (together with its affiliates) would
beneficially own more than 4.99% (or, upon the election of the holder, 9.99%) of the number of shares of the common stock outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the February
2025 Warrants. However,